154
Participants
Start Date
December 31, 2015
Primary Completion Date
January 24, 2017
Study Completion Date
June 13, 2017
FG-4592
Placebo
The Second Hospital of Anhui Medical University, Hefei
301 Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Peking University First Hospital, Beijing
Pekingg University, People's Hospital, Beijing
The First Affiliated hospital of Third Military Medical University (Southwest Hospital), Chongqing
Lan Zhou University Second Hospital, Lanzhou
Guangdong General Hospital, Guangzhou
Nanfang Hospital, Southern Medical University, Guangzhou
Shenzhen People's Hospital, Shenzhen
The First Affiliated hospital of Guangxi Medical University, Nanning
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning
The Second Xiangya Hospital of Central South University, Changsha
The First Hospital of Baotou Medical School of Inner Mongolia University of Science and Technology, Baotou
Jiangsu Province Hospital, Nanjing
Nanjing General Hospital of Nanjing Military Command, Nanjing
Zhongda Hospital Southeast University, Nanjing
The First Affiliated Hospital of Nanchang University, Nanchang
The First Affiliated Hospital of Dalian Medical University, Dalian
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Shandong Provincial Hospital, Jinan
Huashan Hospital of Fudan University, Shanghai
Rui Jin Hospital Shanghai Jiao Tong University School of Medication, Shanghai
Shanghai Changzheng Hospital, Shanghai
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medication, Shanghai
The Second Hospital of Shanxi Medical University, Taiyuan
West China Hospital, Sichuan Universtiy, Chengdu
Tianjin Medical University General Hospital, Tianjin
The First Affiliated Hospital, Zhejiang University, Hangzhou
Ningbo No.2 Hospital, Ningbo
Lead Sponsor
FibroGen
INDUSTRY